Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration

Journal of Clinical Pharmacology

Volumn 47, Issue 11, 2007, Pages 1390-1397

  Fishbane, Steven ^a,c   Pannier, Anne ^b   Liogier, Xavier ^b   Jordan, Paul ^b   Dougherty, Frank C ^b   Reigner, Bruno ^b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c NONE   (United States)

Author keywords

Anemia; C.E.R.A.; Continuous erythropoietin receptor activator; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTIANEMIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR;

ABDOMEN; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARM; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INJECTION VOLUME; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HUMAN; INJECTION SITE; INJECTION SITE INFLAMMATION; INJECTION SITE SWELLING; LABORATORY TEST; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SIDE EFFECT; SINGLE DRUG DOSE; SYNCOPE; THIGH; VITAL SIGN; VOLUNTEER;

ADOLESCENT; ADULT; AGED; ANEMIA; CHRONIC DISEASE; CROSS-OVER STUDIES; DRUG CARRIERS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY DISEASES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS;

EID: 35448969355     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007307570     Document Type: Article

References (22)

1. Brenner BM, Rector FC Haematologic complications of kidney disease. In: Brenner BM, ed. Brenner & Rector's The Kidney. 7 th ed. Philadelphia, PA: Saunders; 2004.
2. Collins A., Ellefson J. Association between hematocrit level and mortality in hemodialysis patients: case study of the anemic patient. Nephrol Nurs J. 2000 ; 27: 233-236.
3. Ross SD, Fahrbach K., Frame D., Scheye R., Connelly JE, Glaspy J. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther. 2003 ; 25: 1786-1805.
4. Deray G. Achieving therapeutic targets in renal anaemia: considering cost-efficacy. Curr Med Res Opin. 2004 ; 20: 1095-1101.
5. Locatelli F., Aljama P., Bárány P., et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004 ; 19 (suppl 2). ii1 - ii47.
6. Xue JL, Ma JZ, Louis TA, Collins AJ Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001 ; 12: 2753-2758.
7. Macdougall IC CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005 ; 4: 436-440.
8. Macdougall IC, Reigner B., Dougherty FC Consistent pharmacokinetic properties of C.E.R.A. (continuous erythropoietin receptor activator) in healthy volunteers and in patients with CKD [abstract 89]. Am J Kidney Dis. 2006 ; 47: A41.
9. Macdougall IC, Robson R., Opatrna S., et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006 ; 1: 1211-1215.
10. Jarsch M., Brandt M., Lanzendörfer M., Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin beta determined by surface plasmon resonance and competition binding assay. Pharmacology. 2008 ; 81: 63-69.
11. Klinger M., Arias M., Vargemezis V., et al on behalf of the AMICUS Study Investigators. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis. In press.
12. Macdougall IC, Walker R., Provenzano R., et al. C.E.R.A. (continuous erythropoietin receptor activator) administered at extended intervals corrects anemia and maintains stable hb levels in patients with ckd not on dialysis [abstract SA-PO208]. J Am Soc Nephrol. 2006 ; 17: 619A.
13. Sulowicz W., Locatelli F., Ryckelynck J-P., et al on behalf of the PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007 ; 2: 637-646.
14. Levin NW, Fishbane S., Valdés Cañedo F., et al on behalf of the MAXIMA Study Investigators. The effect of intravenous C.E.R.A. given every 2 or 4 weeks in maintaining stable control of haemoglobin in chronic kidney disease patients on dialysis. Lancet. In press.
15. Jensen JD, Jensen LW, Madsen JK The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur J Clin Pharmacol. 1994 ; 46: 333-337.
16. Macdougall IC, Jones JM, Robinson MI, Mills JB, Coles GA, Williams JD Subcutaneous erythropoietin therapy: comparison of three different sites of injection. Contrib Nephrol. 1991 ; 88: 152-156.
17. Bazett HC An analysis of the time relations of the electrocardiograms. Heart. 1920 ; 7: 353-370.
18. Halstenson CE, Macres M., Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991 ; 50: 702-712.
19. Macdougall IC, Gray SJ, Elston O., et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999 ; 10: 2392-2395.
20. Dougherty FC, Reigner B., Jordan P., Pannier A. CERA (continuous erythropoiesis receptor activator): dose-response, pharmacokinetics and tolerability in phase I multiple ascending dose studies [abstract 6692]. Proc Am Soc Clin Oncol. 2004 ; 23: 603.
21. Reigner B., Jordan P., Pannier A., Glaspy J. Phase I studies with C.E.R.A. (continuous erythropoietin receptor activator), an innovative erythropoietic agent. [abstract 568]. Eur J Cancer. 2003 ; 1 :(suppl 5). S172.
22. Tare N., Pill J., Haselbeck A. Preclinical pharmacodynamics and pharmacokinetics of CERA (continuous erythropoiesis receptor activator): a new erythropoietic agent for anaemia management in patients with kidney disease. [abstract M526]. Nephrol Dial Transplant. 2003 ; 18 (suppl 4). 166.